Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04635891 · ClinicalTrials.gov registry record
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
A clinical trial of FSHD, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- 450
- Enrollment target
- 20
- Study locations
NCT04635891: Recruiting study of FSHD, sponsored by University of Kansas Medical Center.
NCT04635891 is a study of FSHD that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 450 participants, below the 1,763-participant average among 3 other FSHD trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04635891, a study of FSHD, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and reachable workspace, as well as optional muscle biopsy and wearable device (US participants only).
Primary Outcome
The 10-meter walk/run (previously the 30 foot go) or gait speed task will be performed during study visits. This task tests a range of different abilities, from power, to endurance, and balance. Also, the 10 meter walk/run is a predictor of loss of ambulation in Duchenne Muscular Dystrophy.
Conditions Studied
Study Locations (20)
Texas
- Austin Neuromuscular Center - Austin
- Univeristy of Texas Southwestern Medical Center - Dallas
- University of Texas Health San Antonio - San Antonio
California
- David Geffen School of Medicine at UCLA - Los Angeles
- Neuromuscular Disorders Program at Stanford University School of Medicine - Stanford
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- Univeristy of Florida Gainesville - Gainesville
Iowa
- University of Iowa - Iowa City
Kansas
- Univeristy of Kansas Medical Center - Kansas City
Maryland
- Kennedy Krieger Institute - Baltimore
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2028-01 |
What NCT04635891 shows while recruiting
NCT04635891 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 1,763-participant average among 3 other FSHD trials with a reported enrollment target (74% lower).
The record links to 1 condition, with FSHD appearing as the primary indexed condition, and to 0 interventions.
NCT04635891 names 20 study sites across 17 states, led by Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04635891 about?
NCT04635891 is a clinical study titled "Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)". The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding...
What is the current status of trial NCT04635891?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2020-12-15. Estimated completion is 2028-01.
What conditions does trial NCT04635891 study?
This clinical trial studies the following conditions: FSHD.
Who is sponsoring clinical trial NCT04635891?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04635891 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for FSHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BetterLife FSHD: A Patient-driven Health and Research Platform
RECRUITING
-
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
RECRUITING · Phase 3
-
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI